Reconsidering CAR-T cell therapy for solid tumors / 医学研究生学报

ABSTRACT

Chimeric antigen receptor T cells (CAR-T) have achieved remarkable therapeutic effects in the treatment of malignant hematological tumors, but there are still some problems including poor efficacy and possible toxicity risks in the treatment of solid tumors. This paper analyzes the reasons for the poor efficacy of CAR-T cells in the treatment of solid tumors, including tumor heterogeneity, difficulty in homing of CAR-T cells, immunosuppressive microenvironment, off-target effect,T cell exhaustion and so on, and proposes the strategies and future trends in improving the efficacy of CAR-T in the treatment of solid tumors.